Halozyme Therapeutics (NASDAQ:HALO) Director Sells $107,591.25 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $66.21, for a total value of $107,591.25. Following the transaction, the director owned 43,669 shares of the company’s stock, valued at $2,891,324.49. The trade was a 3.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bernadette Connaughton also recently made the following trade(s):

• On Friday, May 1st, Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $63.48, for a total value of $103,155.00.

Halozyme Therapeutics Trading Up 2.5%

Halozyme Therapeutics stock opened at $71.60 on Friday. Halozyme Therapeutics, Inc. has a 52 week low of $51.06 and a 52 week high of $82.22. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The stock has a market capitalization of $8.49 billion, a P/E ratio of 25.76, a PEG ratio of 0.29 and a beta of 0.88. The stock has a 50-day simple moving average of $66.63 and a 200 day simple moving average of $68.72.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The business had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. During the same quarter last year, the company posted $1.11 earnings per share. Halozyme Therapeutics’s quarterly revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Analysts expect that Halozyme Therapeutics, Inc. will post 7.61 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. UBS Group reiterated a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a report on Wednesday. HC Wainwright lifted their price target on Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday. Wells Fargo & Company boosted their price objective on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. Finally, TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Eight research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $81.60.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Measured Wealth Private Client Group LLC lifted its stake in Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 124 shares during the last quarter. Abel Hall LLC boosted its holdings in Halozyme Therapeutics by 4.2% during the 4th quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock valued at $216,000 after acquiring an additional 129 shares during the period. StoneX Group Inc. boosted its holdings in Halozyme Therapeutics by 3.8% during the 4th quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock valued at $246,000 after acquiring an additional 132 shares during the period. Moran Wealth Management LLC boosted its holdings in Halozyme Therapeutics by 0.4% during the 4th quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company’s stock valued at $2,396,000 after acquiring an additional 151 shares during the period. Finally, Twin Capital Management Inc. boosted its holdings in Halozyme Therapeutics by 1.4% during the 1st quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock valued at $738,000 after acquiring an additional 161 shares during the period. Institutional investors own 97.79% of the company’s stock.

Trending Headlines about Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised earnings forecasts for multiple future periods, including FY2026, FY2027, and FY2028, which strengthens the long-term growth story for Halozyme Therapeutics. Halozyme Therapeutics article
• Positive Sentiment: Analysts also increased estimates for several 2027 quarters, including Q1, Q2, Q3, and Q4, suggesting improving earnings momentum. Halozyme Therapeutics article
• Neutral Sentiment: Some near-term and farther-out estimates were mixed, with a slight cut to Q2 2026 and a reduction in Q1 2028, indicating the outlook improved overall but not across every period. Halozyme Therapeutics article
• Neutral Sentiment: Recent insider sales by the CEO and a director were disclosed, but both were made under pre-arranged 10b5-1 trading plans, which typically makes them less alarming to investors. Halozyme Therapeutics article

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.